Pfizer (PFE) Total Current Liabilities (2016 - 2025)
Pfizer (PFE) has disclosed Total Current Liabilities for 17 consecutive years, with $37.0 billion as the latest value for Q4 2025.
- Quarterly Total Current Liabilities fell 13.98% to $37.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $37.0 billion through Dec 2025, down 13.98% year-over-year, with the annual reading at $37.0 billion for FY2025, 13.98% down from the prior year.
- Total Current Liabilities for Q4 2025 was $37.0 billion at Pfizer, up from $36.6 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $47.8 billion in Q4 2023, with the low at $5.1 billion in Q4 2021.
- Average Total Current Liabilities over 5 years is $35.6 billion, with a median of $37.4 billion recorded in 2025.
- Peak annual rise in Total Current Liabilities hit 494.77% in 2023, while the deepest fall reached 26.92% in 2023.
- Over 5 years, Total Current Liabilities stood at $42.7 billion in 2021, then dropped by 1.25% to $42.1 billion in 2022, then rose by 13.42% to $47.8 billion in 2023, then decreased by 10.04% to $43.0 billion in 2024, then dropped by 13.98% to $37.0 billion in 2025.
- According to Business Quant data, Total Current Liabilities over the past three periods came in at $37.0 billion, $36.6 billion, and $37.7 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.